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A B S T R A C T
Background
Intra-rectal artesunate has been developed as a potentially life-saving treatment of severe
malaria in rural village settings where administration of parenteral antimalarial drugs is not
possible. We studied the population pharmacokinetics of intra-rectal artesunate and the
relationship with parasitological responses in patients with moderately severe falciparum
malaria.
Methods and Findings
Adults and children in Africa and Southeast Asia withmoderately severemalaria were recruited
in two Phase II studies (12 adults from Southeast Asia and 11 children from Africa) with intensive
sampling protocols, and three Phase III studies (44 children from Southeast Asia, and 86 children
and 26 adults from Africa) with sparse sampling. All patients received 10 mg/kg artesunate as a
single intra-rectal dose of suppositories. Venous blood sampleswere taken during a period of 24 h
following dosing. Plasma artesunate and dihydroartemisinin (DHA, the main biologically active
metabolite) concentrations were measured by high-performance liquid chromatography with
electrochemical detection. The pharmacokinetic properties of DHA were determined using
nonlinear mixed-effects modelling. Artesunate is rapidly hydrolysed in vivo to DHA, and this
contributes the majority of antimalarial activity. For DHA, a one-compartment model assuming
complete conversion from artesunate and first-order appearance and elimination kinetics gave
the best fit to the data. Themean population estimate of apparent clearance (CL/F) was 2.64 (l/kg/
h) with 66% inter-individual variability. The apparent volume of distribution (V/F) was 2.75 (l/kg)
with 96% inter-individual variability. The estimated DHA population mean elimination half-life
was 43 min. Gender was associated with increased mean CL/F by 1.14 (95% CI: 0.36–1.92) (l/kg/h)
for a male compared with a female, and weight was positively associated with V/F. Larger V/Fs
were observed for the patients requiring early rescue treatment compared with the remainder,
independent of any confounders. No associations between the parasitological responses and the
posterior individual estimates of V/F, CL/F, and AUC0–6h were observed.
Conclusions
The pharmacokinetic properties of DHA were affected only by gender and body weight.
Patients with the lowest area under the DHA concentration curve did not have slower parasite
clearance, suggesting that rectal artesunate is well absorbed in most patients with moderately
severe malaria. However, a number of modelling assumptions were required due to the large
intra- and inter-individual variability of the DHA concentrations.
The Editors’ Summary of this article follows the references.
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Introduction
Artemisinin and its derivatives are the most important class
of antimalarial drug. Together with Cinchona alkaloids, they
are the only drugs used to treat severe malaria when oral
treatment is precluded, and recent evidence shows that
parenteral artesunate (ARS) is the treatment of choice in
adults hospitalised with severe malaria [1]. Although the
parenteral route is preferred whenever facilities are available
to diagnose and treat moderate or severe malaria, these
facilities are usually lacking in the rural tropical villages
where most cases arise. In these circumstances, the intra-
rectal route for giving antimalarials has been suggested as an
alternative to parenteral treatments [2–6]. Based on these
observations, a development programme was implemented by
World Health Organization–Special Programme for Research
and Training in Tropical Diseases (WHO–TDR) in 1996 to
deﬁne the pharmacokinetics, safety, and efﬁcacy of intra-
rectal ARS and to register an appropriate formulation for
initial malaria treatment in situations in which oral treatment
could not be taken yet facilities for parenteral treatment were
unavailable. The reasons for supporting this strategy were: (1)
facilities for parenteral treatment are lacking in most rural
tropical settings where malaria ﬁrst presents; (2) it may take
many hours or even days for sick patients to reach facilities
where malaria can be managed by adequate diagnostic testing
and effective parenteral treatments; (3) ARS is the safest and
most rapidly effective antimalarial available [7,8]; and (4)
there was already clinical experience of the efﬁcacy and safety
of intra-rectal artemisinin suppositories.
The efﬁcacy and safety of intra-rectal ARS has been studied
in patients with malaria in Africa and Southeast Asia. Several
conventional pharmacokinetic analyses and some population
pharmacokinetic studies have been performed [9–12]. This
paper aims to present a comprehensive population pharma-
cokinetic analysis of the Phase II and III studies performed
both in children and adults with moderately severe malaria.
Additionally, the relationship between pharmacokinetic
parameters and important clinical and parasitological vari-
ables is assessed.
Methods
Pharmacokinetic data were collected prospectively from
two Phase II and three Phase III studies. One of these has
been published previously after conventional pharmacoki-
netic analysis [10]. Each study was approved by the relevant
local ethics committee, and all were approved by the
Secretariat Committee on Research Involving Human Sub-
jects (SCRIHS) of the World Health Organization, now named
WHO Ethical Review Committee (ERC). Written informed
consent was obtained from all patients or guardians/relatives.
Details of study sites, patient age groups, and blood sampling
schedules for drug assays are given in Table 1.
Patients
Inclusion criteria. Patients in Ghana, Malawi, South Africa,
and Bangkok had moderately severe falciparum malaria [13]
(overall asexual parasite density range 0.1%–27%), were
unable to tolerate oral medication, but did not show clinical
signs or laboratory features of severe malaria (deﬁned below).
Patients from Mae-Sot, Thailand, were enrolled only if they
had hyperparasitaemia deﬁned as parasitaemia 4% [14].
Patients studied in Bangkok were enrolled only if para-
sitaemia exceeded 100,000/ll.
Exclusion criteria. Patients with severe malaria (cerebral
malaria, hypoglycaemia, hyperlactataemia, severe anaemia),
recurrent convulsions, acute diarrhoea, diseases of the
rectum, rectal surgery, known treatment with an effective
antimalarial within 24 h of presentation, pregnant or breast
feeding, with .20% parasitaemia, or with known hyper-
sensitivity to the treatment drugs were excluded from this
study. For exclusion purposes cerebral malaria was classiﬁed
differently in the various countries (Malawi, Ghana, South
Africa: Blantyre coma score ,3; Mae-Sot: Blantyre coma
score ,5). The cut-off for severe anaemia was a haematocrit
of 15% in South Africa and Mae-Sot; and 18% in Malawi,
Bangkok, and Ghana. Patients with hyperlactataemia (deﬁned
as venous plasma lactate levels 5 mmol/l) were excluded only
in the case of South Africa and Ghana. As lactate levels were
not available at the time of enrolment in Malawi and the Thai
studies, patients were not excluded on that basis.
Dosing. All patients received the nearest approximation to
10 mg/kg intra-rectal ARS as a single dose (the range of actual
doses by study site is given in Table 2). The dose formulations
were suppositories of 50 mg and 200 mg (Mepha Pharma-
ceuticals, Aesch-Basle, Switzerland).
There being no data on the reliability of drug absorption in
this group of patients, all studies were open label, with rescue
criteria speciﬁed for the ARS group on the grounds of clinical
deterioration or unsatisfactory parasitological response in
the Phase II trials in Bangkok and Ghana. In the trials in
Malawi, South Africa, and Mae-Sot, patients treated with
rectal ARS were to be rescued if their parasitaemia did not
decline to below 60% of baseline parasitaemia at 12 h unless
their condition was improving clinically. In Malawi and South
Africa the patient was also treated with quinine if the patient
subsequently developed any features of the exclusion criteria
in the period of 24 h of observation following rectal
treatment. Rescue criteria were speciﬁed for the comparator
drug in the South African and Thai trials. Follow-up oral
treatments were chloroquine (except in the case of chlor-
oquine intolerance) in Ghana, sulphadoxine-pyrimethamine
in Malawi and South Africa, oral ARS in Mae-Sot, and
meﬂoquine in Bangkok.
Collection and Analysis of Samples
In the Phase II studies, blood samples were taken at ﬁxed
intervals eight times (15 min, 30 min, 60 min, 90 min, 2 h, 4 h,
8 h, and 12 h) post treatment in Ghanaian children and nine
times (30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, and 12 h)
in Thai adults after administration of rectal ARS. In the Phase
III South Africa study, timed sampling was taken at 1 h, 2 h, 4
h, 6 h, and 8 h post treatment. In parallel studies in Malawi
and Mae-Sot, randomised sparse sampling was employed.
Three plasma samples were taken for each individual
recruited into the trial, the timing of each sample determined
by randomisation within three blocks (0.2–3.9 h, 4–7.9 h, and
8–24 h) during the ﬁrst 24-h period post treatment. Because
drug concentrations were rarely measurable after 12 h, the
protocol was amended during the study to sample between
0.25–1.9 h, 2–5.9 h, and 6–12 h.
Sample volumes obtained at each time point (Table 1)
varied between 1 ml and 10 ml, depending upon the age of
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the patient. Whole blood was collected into appropriately
labelled, heparinised (30IU) tubes, and plasma was separated
within 30 min of collection by centrifugation at 1,0003 g for
15 min. Samples were stored in plastic cryotubes (Nalgene,
Rochester, New York, United States), transported on dry ice,
and stored below70 8C. The longest interval between sample
collection and analysis was 6 mo.
Concentrations of ARS and dihydroartemisinin (DHA) in
plasma were determined by a speciﬁc and sensitive high-
performance liquid chromatographic method with Electro-
Chemical Detector (Model BAS 200A, West Lafayette,
Indiana, United States) operating in the reductive mode, as
described previously [15]. All samples were assayed at the
same laboratory. The mean recovery of ARS and DHA over a
concentration range of 50–200 ng/ml was 75.5% and 93.5%,
respectively. The within-day coefﬁcients of variation were
4.2–7.4% for ARS and 2.6–4.9% for DHA. The day-to-day
coefﬁcients of variation were 1.6–9.6% and 0.5–8.3%,
respectively. The minimum detectable concentration for
both ARS and DHA in plasma was 8 ng/ml. The upper limit
of the assay was 3,200 ng/ml with a limit of quantiﬁcation of
50 ng/ml for all study sites except Mae-Sot, where the limit of
quantiﬁcation was 20 ng/ml. All samples were analysed
according to principles and standards of Good Laboratory
Practice.
Population Pharmacokinetic Modelling
One-compartment and two-compartment models were
ﬁtted to the ARS and DHA concentrations. It was assumed
that ARS was converted completely to DHA (i.e., there was no
other signiﬁcant route of ARS elimination) for determination
of the dose in the pharmacokinetic analyses of the DHA
concentrations. The exact dose (mg/kg) administered was
used in the modelling. Inter-individual variability in the
pharmacokinetic parameters was modelled with log-normal
error models.
For example:
ðCL=FÞi ¼ ðCL=FÞ3 expðgiÞ ð1Þ
where CL/Fi is the pharmacokinetic parameter for the
individual ‘‘i’’ and CL/F is the population mean. The gi
CL/F
is the random effect with zero mean and variance r2CL/F,
which represents the inter-individual variability for the
parameter.
The magnitude of the inter-individual variability was
expressed as a coefﬁcient of variation (%CV; approximated
by the square root of the variance estimate).
Table 1. Study Sites and Sampling Times
Phase Study Site Number of Patients Age Range Sampling Times (h)
Phase II Bangkok, Thailand 12 16–50 y 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12
Ghanaa 11 2–7 y 0, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12
Phase III Mae-Sot, Thailand 44 11 mo–15 y 0; 0.2–3.9; 4–7.9; 8–24b
Malawi 86 16 mo–10 y 0; 0.2–3.9; 4–7.9; 8–24b
South Africa 26 16–58 y 0, 1, 2, 4, 6, 8
aPreviously published [10].
bOne sample was obtained between the times indicated at an exact time determined after randomisation, giving four samples per patient (including the pre-dose sample).
doi:10.1371/journal.pmed.0030444.t001
Table 2. Demographic and Clinical Data of All Patients
Demographic or
Clinical Factor
Number Phase II:
Bangkok
(n ¼ 12)
Phase II:
Ghana
(n ¼ 11)
Phase III:
Mae-Sot
(n ¼ 44)
Phase III:
Malawi
(n ¼ 86)
Phase III:
South Africa
(n ¼ 26)
Mean actual dose of ARS,
mg/kg (SD) [range]
10.0 (1.2) [8.2, 12.0] 9.2 (1.9) [6.9, 11.8] 10.3 (0.8) [8.3, 11.8] 11.0 (1.2) [9.1, 13.6] 9.9 (0.2) [9.6, 10.4]
Percent males 42 55 39 62 58
Mean body weight, kg (SD)
[range]
48.0 (7.06) [40, 60] 14.91 (3.61) [11, 23] 19.13 (9.30) [9.0, 41.5] 14.23 (3.73) [7.6, 25.4] 61.92 (10.0) [40, 86]
Total number of suppositories 1 (percent) 0 3 (27.3) 9 (20.5) 21 (24.4) 0
2 (percent) 7 (58.3) 8 (72.7) 19 (43.2) 21 (24.4) 1 (3.8)
3 (percent) 5 (41.7) 0 14 (31.8) 44 (51.2) 8 (30.8)
4 (percent) 0 0 2 (4.5) 0 8 (30.8)
5 (percent) 0 0 0 0 8 (30.8)
6 (percent) 0 0 0 0 1 (3.8)
Expelled suppositories
(percent)
1 (8.3) 0 2 (4.5) 16 (18.6) 2 (7.6)
Blantyre coma score 3 (percent) Not assessed 0 0 4 (4.7) 0
4 (percent) Not assessed 0 0 11 (12.8) 0
5 (percent) Not assessed 10 (100) 44 (100) 71 (82.6) 26 (100)
doi:10.1371/journal.pmed.0030444.t002
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Various models for the residual intra-individual error (eij)
were compared. Drug concentrations that were below the
limit of quantiﬁcation (LOQ) or above the assay range (i.e.,
.3,200 ng/ml) were included in the analyses because a large
number of these levels are present and exclusion would
reduce the power of the statistical modelling. A covariate
representing the type of drug level (i.e., normal level versus
below-LOQ level versus above-range level) was explored to
investigate the differences in the magnitude of the residual
intra-individual error.
The NLME procedure [16] of the S-PLUS data programme
(S-PLUS 6.2 for Windows, Insightful, Seattle, Washington,
United States) was used to calculate estimates of the
population pharmacokinetic parameters, and the variances
of the inter-patient and intra-patient (e) error. Convergence
was achieved when the objective value did not differ by more
than a pre-speciﬁed difference (0.0001) and the programme
returned the ﬁnal estimates of the population pharmacoki-
netic parameters. The objective function (minus twice the
log-likelihood of the data) was used to determine the model
that best ﬁtted the data. A signiﬁcant drop in the objective
function (using the chi-squared distribution with degrees of
freedom equal to number of parameters that are set equal to
a ﬁxed value in the restricted model) from the general model
to the restricted model was used to determine the ﬁnal
pharmacokinetic model. The goodness of ﬁt of each model
was also determined by the precision of the parameter
estimates and examination of the scatter plot of residuals
versus predicted concentrations. The individual pharmaco-
kinetic parameters were calculated using the posterior
estimates.
Covariates
The covariates recorded in all studies and investigated were
age, body weight (kg), gender, geographic group (Southeast
Asia versus Africa), number of suppositories, baseline para-
sitaemia (/ll), baseline venous plasma lactate (mmol/l), base-
line plasma glucose (mmol/l), and baseline packed cell volume
(PCV). Baseline lactate and glucose levels were not measured
at the Mae-Sot study site. Therefore, the patients from Mae-
Sot were excluded from the covariate analysis of lactate and
glucose. All covariates selected were deemed important a
priori by the study investigators.
In the population pharmacokinetic modelling, covariates
that were continuous variables (except weight) were centred
around their median values so that the population estimates
would represent those of an average patient. Body weight was
included in the model using allometric scaling, i.e., (weight/
70) for V/F and (weight/70)0.75 for CL/F. A statistically
signiﬁcant improvement in the objective function, improve-
ment in the precision of the parameter estimate (standard
error), and reduction in inter-individual and intra-individual
variability were used to determine the importance of the
covariates as predictors.
Pharmacodynamics
To investigate the relationship between pharmacokinetic
parameters (posterior individual estimates of CL/F, V/F, and
area under the plasma concentration time curve (AUC) in the
ﬁrst 6 h [AUC0–6h]) and pharmacodynamics of the drug, the
following prospectively deﬁned pharmacodynamic measures
were explored: (a) Treatment failure (death or malaria
positive smear from day 7 to 28 or undetermined response
[no smear or drop out]) versus success (survival and negative
smear from day 7 to 28). The rectal treatment was not a
curative treatment, so recrudescence depended also on
subsequent treatment. (b) Whether the patient received
rescue treatment (absconded or death or rescued versus not
rescued). (c) Failure of baseline parasitaemia to fall 40% by 12
h (PC60). (d) Time for baseline parasitaemia to fall by 50%
(PCT50) and 90% (PCT90). These parasite clearance times
were determined from parasite counts recorded 6-hourly for
all study sites except Ghana, where the parasite count of each
child was determined every 4 h.
Multiple linear or logistic regressions, where appropriate,
were performed to model the relationship between the
pharmacodynamic measures (PCT50, PCT90, treatment out-
come, early rescue treatment, PC60), and the independent
variables: posterior individual estimates of CL/F, V/F, and
AUC0–6h, parasitaemia at admission (log transformed), base-
line packed-cell volume, age, and gender.
Results
Demographic, clinical, parasitological, and laboratory data
for all patients by study site are presented in Tables 2 and 3.
All patients fulﬁlled the criteria for moderately severe
malaria with parasitaemias .0.1%, moderately elevated
plasma lactate levels (except in Bangkok and Malawi, where
three and seven patients, respectively, had lactate concen-
trations .5 mmol/l), and moderate anaemia. The total
number of suppositories given to each patient was usually
between one and three (89%), although up to six supposito-
ries were given to South African adults. Few (,10%)
suppositories were expelled, the exception being Malawi,
where 19% of children expelled suppositories.
Safety and Clinical Efficacy
One patient from Mae-Sot died. The most likely cause of
death was considered to be over-transfusion of 5% dextrose
leading to iatrogenic water intoxication. Nineteen patients
required rescue treatment (Table 4).
The integrated adverse-event count yielded 66 adverse
events from the 179 patients. The leading adverse events
reported were gastrointestinal (mostly nausea, vomiting, and
abdominal pain). For ﬁve patients, central nervous system or
neurological adverse events were observed. These were
convulsions, dizziness, impairment of consciousness, abnor-
mal reﬂexes, and vertigo. However, none of the reported
events led to treatment discontinuation or were classiﬁed as
causally related to rectal ARS therapy.
Artesunate Pharmacokinetics
A total of 307 levels from 136 patients were available for
the statistical modelling (one outlier with an ARS concen-
tration of 9,224 ng/ml 13 min after drug administration was
excluded because of the likelihood of sample contamination).
Of these, 32 (10.4%) levels were below the limit of
quantiﬁcation and one (0.3%) level was above the range.
Figure 1 shows a scatter plot of the observed ARS
concentrations versus time, by study site. There are no major
differences in the distribution of data across the ﬁve different
study sites. A clear pharmacokinetic proﬁle is difﬁcult to
discern, precluding formal pharmacokinetic modelling. The
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e4442116
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median (range) of the observed individual peak concentra-
tions was 269 ng/ml (11–4,720 ng/ml).
DHA Pharmacokinetics
A total of 424 levels were available for statistical modelling
from 164 patients (three outliers were excluded with levels
.6,000 ng/ml). Of these, 33 (7.8%) levels were below the limit
of detection and three (0.7%) were above the range. Figure 2
shows a scatter plot of the observed DHA concentrations
versus time, by study site. A one-compartment model with
ﬁrst-order appearance and elimination kinetics including lag
time best ﬁts the data (appearance rate was ﬁxed at 0.2/h and
lag time at 0.14 h).
The data did not support a full variance–covariance matrix
for the random effects of CL/F and V/F. The mean population
estimate of CL/F was 2.64 (l/kg/h) with 66% inter-patient
variability, and V/F was 2.75 (l/kg) with 96% inter-patient
variability. These estimates correspond to an elimination half-
life of 43min. The residual errormodel that gave theminimum
value for the objective function was a lognormal residual error
model for all the data. Including a covariate for ‘‘study site’’ or
‘‘levels outside the limits of the assay’’ in the residual error
modelling did not improve the objective function. Figure 2
shows the observed and population-predicted concentrations
versus time. The residual plot indicated no bias in estimation
(see Figure 3), and the patient-speciﬁc proﬁles were charac-
terised adequately (unpublished data).
Relationship between DHA Pharmacokinetic Variables and
Covariates
A total of 164 of the 179 patients had posterior individual
estimates of CL/F and V/F derived from the population
pharmacokinetic modelling of DHA.
Age, Body Weight, Gender, and Geographic Group
(Southeast Asia versus Africa)
When age was treated as a dichotomous variable, children
(age 15 y) versus adults (age .15 y), there was no signiﬁcant
difference between adults and children for the distribution of
the patient-speciﬁc deviations from the population estimate
of CL/F (gCL/F), whereas the patient-speciﬁc deviations from
the population estimate of V/F (gV/F) were higher for adults
compared with children (p , 0.001). No correlation was
observed between gCL/F and body weight, whereas there was a
positive correlation between gV/F and body weight (r¼ 0.42).
There was no signiﬁcant difference between males and
females for the distribution of gV/F, whereas signiﬁcantly
higher values of gCL/F were observed for males compared with
females (p ¼ 0.003). There were no signiﬁcant differences
between patients from Southeast Asia and Africa, for both
the distributions of gCL/F and gV/F.
Baseline Parasitaemia, PCV, Lactate and Glucose, and
Number of Suppositories
No correlations were observed between gCL/F and gV/F and
baseline parasitaemia, lactate and glucose, and baseline PCV
and gCL/F. There was a positive correlation between baseline
PCV and gV/F (r ¼ 0.22, p ¼ 0.005). There were no signiﬁcant
differences between both the distributions of gCL/F and gV/F
for the number of suppositories given (either one, two, or
three or more).
Table 5 presents the ﬁnal population parameter estimatesTa
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and the inter-individual and intra-individual variability.
Including the covariates ‘‘gender’’ and ‘‘body weight’’
reduced the inter-individual variability of CL/F from 66%
to 62% and V/F from 96% to 75%, respectively. The addition
of baseline PCV and age did not signiﬁcantly improve the
objective function.
Relationship between DHA Pharmacokinetic Parameters
and Pharmacodynamic Variables
The pharmacodynamic variables deﬁned prospectively as
important were treatment outcome, early rescue treatment,
failure of baseline parasitaemia to fall 40% by 12 h (PC60),
and time to clear 50% (PCT50) and 90% (PCT90) of baseline
parasitaemia.
The DHA pharmacokinetic parameters (available for 164 of
the 179 study participants) investigated were posterior
individual estimates of CL/F, V/F, and AUC0–6h.
Treatment Outcome
For the statistical modelling, treatment outcome was a
dichotomous variable with death, positive smear from day 7
to day 28, or undetermined response grouped together
Table 4. Efficacy Data of All Patients
Outcome Variable Category Phase II:
Bangkok
(n ¼ 12)
Phase II:
Ghana
(n ¼ 11)
Phase III:
Mae-Sot
(n ¼ 44)
Phase III:
Malawi
(n ¼ 86)
Phase III:
South Africa
(n ¼ 26)
Treatment outcome Death (percent) 0 0 1 (2.3) 0 0
Ra (percent) 2 (16.7) 4 (36.4) 0 39 (45.3) 1 (3.8)
R/Sb (percent) 3 (25.0) 3 (27.3) 16 (36.4) 29 (33.7) 2 (7.7)
Sc (percent) 7 (58.3) 4 (36.4) 27 (61.4) 18 (20.9) 23 (88.5)
Rescue treatment and
clinical deterioration
Absconded (percent) 0 0 0 1 (1.2) 0
Death (percent) 0 0 1 (2.3) 0 0
Rescued (percent) 0 0 8 (18.2) 9 (10.5) 2 (7.7)
Not rescued (percent) 12 (100) 11 (100) 35 (79.5) 76 (88.4) 24 (92.3)
PC60d (percent) 5 (41.7) 0 (0) 9 (20.9)g 7 (8.1) 1 (3.8)
Median PCT50
e, h [range] 15 [6–24] 8 [4–12] 12 [6–24] 12 [6–36] 12 [6–24]
Median PCT90
f, h [range] 18 [6–30] 16 [8–20] 18 [6–30]g 18 [6–36] 18 [6–30]
aR, positive smear from day 7 to 28.
bR/S, undetermined response (no smear or drop out).
cS, negative smear from day 7 to 28.
dPC60, failure of baseline parasitaemia to fall 40% by 12 h.
ePCT50, time to clear 50% of baseline parasitaemia.
fPCT90, time to clear 90% of baseline parasitaemia.
gMissing for one patient.
doi:10.1371/journal.pmed.0030444.t004
Figure 1. Observed Artesunate Concentrations (Semilogarithmic Scale; ng/ml) versus Time post Dose (h)
Study site: filled circle, Bangkok; open square, Ghana; filled triangle, Mae-Sot; open circle, Malawi; asterisk, South Africa.
doi:10.1371/journal.pmed.0030444.g001
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(termed ‘‘treatment failure’’, n ¼ 91) versus ‘‘treatment
success’’ (negative smear from day 7 to day 28; n ¼ 73). This
deﬁnition of treatment outcome does not include the ‘‘early
rescues’’, which are considered under the ‘‘Early rescue
treatment’’ section below.
No signiﬁcant difference in the distribution of the
posterior individual estimates of CL/F and AUC0–6h was
observed between the two groups of patients, treatment
failure, and treatment success. Patients who had failed their
treatment (n ¼ 91) had signiﬁcantly lower values of V/F
compared with those with treatment success (n ¼ 73)
(geometric mean [95% CI]: 2.46 [2.25, 2.66] versus 3.16 [2.80,
3.60] l/kg; p ¼ 0.001), but after multiple logistic regression
analysis, with adjustment for baseline parasitaemia, baseline
PCV, age, and gender (i.e., pre-deﬁned confounders), no
signiﬁcant association between V/F and ‘‘treatment outcome’’
was observed (p ¼ 0.12). The observed univariate association
Figure 2. Observed and Population Predicted Concentrations (Solid Black Line) of DHA (Semilogarithmic Scale; ng/ml) versus Time post Dose (h)
Study site: filled circle, Bangkok; open square, Ghana; filled triangle, Mae-Sot; open circle, Malawi; asterisk, South Africa.
The population predicted concentrations are calculated for a dose of 10 mg/kg.
doi:10.1371/journal.pmed.0030444.g002
Figure 3. Residual (loge Units) versus Population Predicted Concentrations of DHA (loge Units)
Residual¼ observed  population predicted concentration of DHA.
doi:10.1371/journal.pmed.0030444.g003
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between ‘‘treatment outcome’’ and V/F was confounded by
age.
Early Rescue Treatment
For the statistical modelling, rescue treatment was a
dichotomous variable with absconded, death, or rescued by
day 7 grouped together (n¼ 16) versus not rescued (n¼ 148).
No signiﬁcant association between rescue treatment and both
CL/F and AUC0–6h was observed. Those rescued had slightly
higher values of V/F compared with those patients not
requiring rescue treatment (geometric mean [95% CI]: 3.42
[2.58, 4.53] versus 2.69 [2.49, 2.90] l/kg, p ¼ 0.056). From the
multiple logistic regression analysis with adjustment for
confounders, a signiﬁcant association between V/F and
‘‘rescue treatment’’ was observed (p ¼ 0.01). As the V/F
increased, so did the risk of requiring rescue treatment (see
Figure 4). Whether this reﬂected a truly larger apparent
volume of distribution or a reduced fraction of drug
absorbed (F) cannot be distinguished.
Failure of Baseline Parasitaemia to Fall 40% by 12 h
There were 20 patients whose parasitaemia failed to drop
by 40% of baseline values by 12 h. No signiﬁcant association
between failure and both CL/F and AUC0–6h was observed,
but patients who failed to drop parasitaemia by 40% by 12 h
had higher V/F values compared with the remainder (geo-
metric mean [95% CI]: 3.36 [2.17, 3.63] versus 2.67 [2.44, 2.80]
l/kg; p ¼ 0.045). Multiple logistic regression analysis with
adjustment for confounders showed no signiﬁcant association
between V/F and ‘‘failure to drop to 60% parasitaemia at 12
h’’ (p ¼ 0.09).
Time to Clear 50% (PCT50) and 90% (PCT90) of Baseline
Parasitaemia
Two adult patients from South Africa with baseline
parasitaemia ,10,000/ll were excluded from the analyses of
the efﬁcacy variables, PCT50 and PCT90. No signiﬁcant
correlations between both PCT50 and PCT90 and the
pharmacokinetic parameters CL/F, V/F, and AUC0–6h were
observed (Spearman rank correlation coefﬁcients ranged
from 0.07 to 0.17). These results were unchanged when
adjusting for baseline parasitaemia, PCV, gender, and age.
Figures 5A and 5B illustrate the lack of association between
PCT50, PCT90, and AUC0–6h, respectively.
As ARS is rapidly hydrolysed in vivo to DHA and both have
approximately equal antimalarial activity, the molar sums of
ARS plus DHA plasma concentrations were also modelled. A
total of 442 ARS-plus-DHA levels from 168 patients were
available. The associations between the posterior individual
PK parameters of ARS plus DHA (i.e., CL/F, V/F, and AUC0–6)
and the efﬁcacy variables (deﬁned above) were the same as
observed for the posterior individual PK parameters of DHA
alone (unpublished data).
Discussion
Malaria can evolve rapidly from uncomplicated to severe
disease and death if not properly treated. Patients who
cannot take oral treatment reliably are in serious danger and
must be treated without delay. Rectal ARS provides the most
rapidly effective available antimalarial in a simple and easily
administered formulation. Earlier conventional pharmacoki-
netic studies compared 10-mg/kg doses and 20-mg/kg doses in
both adults and children, and showed no signiﬁcant pharma-
codynamic differences between the two treatment groups and
gave no safety concerns [10]. But in treating a rapidly life-
threatening infection, deﬁning the speed and reliability of
absorption is critical. If even a small proportion of patients
malabsorb the drug, this would be a major concern.
This pharmacokinetic analysis aimed to develop and test a
population pharmacokinetic model of intra-rectal ARS, using
data obtained from studies that were coordinated in design
and analysis. Patient samples were handled in a standardised
fashion and drug assays performed in one laboratory, to
minimise assay variability. In addition to demographic
variables and clinical and parasite response, it was antici-
pated that the number of suppositories and severity of
disease might inﬂuence bioavailability. Bioavailability in
patients failing treatment—judged either through parasito-
Table 5. Population Pharmacokinetic Parameters for DHA
Parameter Estimate
(Standard Error)
ka (/h)—fixed 0.2
Increase in CL/F (l/kg/h) for a male 1.14 (0.40)
CL/F (l/kg/h) for a: Male 3.17
Female 2.03
Increase in V/F per unit (l/70 kg) 5.77 (0.55)
Intercept 0.57 (1.68)
V/F (l/kg) for a body weight of: 15 kg 1.81
30 kg 3.04
60 kg 5.52
70 kg 6.34
Lag time (h)—fixed 0.14
Inter-individual variability for CL/Fa 62
Inter-individual variability for V/Fa 75
Intra-individual variabilitya 93
aPercent CV.
doi:10.1371/journal.pmed.0030444.t005
Figure 4. Relationship of Estimated Probability of Requiring Rescue
Treatment and V/F of DHA (l/kg)
Derived from a multiple logistic regression model with adjustment for
the confounders: baseline parasitaemia, baseline PCV, age, and gender.
doi:10.1371/journal.pmed.0030444.g004
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logical effect or clinical response—was considered critical;
therefore, a sample for pharmacokinetic analysis was ob-
tained just prior to rescue, for such patients.
As other pharmacokinetic studies of ARS have observed
[11], compartmental modelling for ARS data requires
frequent sampling [17,18] because ARS is rapidly and
extensively metabolised to the active metabolite, DHA
[19,20]. Our data consisted of a mixture of rich and sparse
sampling with considerable inter-patient variability in the
ARS concentrations, which has been observed elsewhere
[9,10,21], and as a result it was not possible to ﬁt a
pharmacokinetic model to the data. ARS concentrations
were still observed 6 h post dosage in some patients in this
dataset, suggesting that absorption may have become rate-
limiting for ARS clearance. This has also been observed for
parenteral ARS [18,22], and differs from oral administration,
which produces lower and shorter-lived ARS levels.
The model that best ﬁtted the DHA data was a one-
compartment model with ﬁrst-order appearance and elimi-
nation kinetics including lag time. Due to the sparseness and
erratic nature of the data, both the appearance rate constant
and lag time were ﬁxed so that a satisfactory model ﬁt could
be obtained. Other studies have also used one-compartment
models for DHA pharmacokinetics [10,23]. However, the
choice of this model may reﬂect relatively lower sampling
frequency, as more frequent sampling identiﬁed two-com-
partment modelling as being more appropriate in analysing
DHA after parenteral ARS [18]. The mean population
estimate of CL/F was 2.64 (l/kg/h), and volume of distribution
(V/F) was 2.75 (l/kg), giving an elimination half-life of 43 min
for DHA. These estimates are similar to those reported
previously [10,11,23]. The ﬁxed value of the appearance rate
constant was slower than the estimated elimination rate
constant, suggesting that the ARS rectal capsules are
absorption rate limited. Therefore, the appearance rate of
DHA will include both the absorption and elimination of
ARS. The population-predicted proﬁle of DHA was similar to
that observed by Karunajeewa et al [11], with the maximum
concentration occurring at approximately 3 h.
We observed a high intra-individual variability (93%) of
DHA, as well as considerable inter-individual variability for
both CL/F (66%) and V/F (96%). The F is not known;
therefore, an increase in estimated CL/F or V/F could result
from either an increase in clearance or volume or a reduction
in F. Additionally, since it was not possible to estimate the
appearance rate constant and the inter-individual variability
of the appearance rate constant, changes in V/F may be due to
changes in the appearance rate constant. This would have
implications for treatment of patients with severe malaria, in
whom speed of absorption is vital. Gender was observed to
have a signiﬁcant effect on CL/F, giving population estimates
for CL/F of 3.17 (l/kg/h) and 2.03 (l/kg/h) for males and females,
respectively. Body weight was observed to have a signiﬁcant
effect on V/F: the population estimates of V/F were 1.81 (l/kg)
for a body weight of 15 kg, 3.04 l/kg for 30 kg, 5.52 l/kg for 60
kg, and 6.34 l/kg for 70 kg. Patients from different geographic
areas were not observed to have different pharmacokinetic
parameters.
Higher DHA V/Fs were observed for patients requiring
‘‘rescue treatment’’ compared with those patients not
requiring rescue treatment, independent of the confounders,
baseline parasitaemia, baseline PCV, age, and gender.
Although this may reﬂect either reduced absorption (i.e.,
smaller F) or a truly larger apparent volume of distribution,
further investigation to relate initial plasma concentrations
of DHA and ARS þ DHA (using AUC in the ﬁrst 6 h) to
parasite reduction failed to show signiﬁcant relationships.
The principal, directly measurable, pharmacodynamic effect
of these compounds is to reduce parasitaemia rapidly by
accelerating ring form clearance. Thus, inadequate early
absorption would be expected to lead to a relationship
between the AUC for ARS and DHA together and rate of
parasitaemia reduction. This was not seen; patients with the
lowest AUCs did not have discernibly slower parasite
clearance. This suggests that maximal effects are achieved
rapidly in nearly all patients, and that rectal ARS is a
promising treatment for moderately severe malaria. How-
Figure 5. Observed PCT50 (A) and PCT90 (B) versus Posterior Estimate of
DHA AUC0–6h (ng/ml3 h)
For 162 patients (two patients excluded due to baseline parasitaemia
,10,000/ll).
doi:10.1371/journal.pmed.0030444.g005
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ever, these pharmacokinetic ﬁndings should be interpreted
with caution: (i) the appearance rate constant of DHA was
ﬁxed in the modelling, (ii) there was large inter- and intra-
patient variability in both the ARS and DHA concentrations,
(iii) it was not possible to derive the pharmacokinetics of ARS,
and (iv) the DHA pharmacokinetic parameters were inﬂu-
enced by both the absorption and clearance of ARS.
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Editors’ Summary
Background. More than 40% of the world’s population is at risk of
malaria, a tropical parasitic disease that is transmitted between people
by infected mosquitoes. Malaria parasites cause a ’flu-like illness that
includes chills, fevers, headaches, and sometimes nausea and vomiting. If
untreated, people with malaria can rapidly become anemic—the parasite
destroys their red blood cells—or can develop complications that
damage the brain and other organs. Severe malaria can be fatal and
must be treated quickly. It has become a matter of great concern that
the parasite has developed resistance to most of the drugs used to treat
or prevent malaria. In the past few years, artemisinin derivatives have
been shown to be an effective new form of treatment. Artemisinin
derivatives are effective, rapid-acting antimalarial drugs—wormwood,
the plant source of artemisinin, is an ancient Chinese cure for malaria.
Artesunate, a water-soluble derivative of artemisinin, can be given as
tablets or as injections. However, people with severe malaria often
cannot take oral medicines, and in rural settings in the developing world,
artesunate injections are usually impracticable. Consequently, rectal
artesunate suppositories have been developed to provide first-line
treatment of severe malaria in these settings. This simple dosing method
can ‘‘buy’’ patients valuable time during which they can be moved to a
hospital for further treatment.
Why Was This Study Done? When treating severe malaria, it is
important that every patient absorbs the antimalarial drug rapidly and
efficiently into their blood. If even a small proportion of patients
malabsorb the drug, many people could die. How the body processes a
drug is known as pharmacokinetics, and although some pharmacokinetic
studies have investigated how the body processes artesunate given in
rectal suppositories, relatively little is know about the population
pharmacokinetics of artesunate given this way. That is, the patient
characteristics that affect the processing of intra-rectal artesunate are not
known, and it is unclear whether a small proportion of the population
might fail to absorb the drug given via this route. In this study, the
researchers have developed and tested a population pharmacokinetic
model for artesunate given rectally to children and adults with
moderately severe malaria.
What Did the Researchers Do and Find? The researchers took serial
blood samples from nearly 200 patients with moderately severe malaria
in Africa and Southeast Asia for the first 24 hours after they received a
rectal artesunate suppository. They measured the levels of artesunate
and dihydroartemisinin (DHA; the body rapidly converts artesunate to
DHA, which kills the malaria parasites) in these samples and used these
data to build a pharmacokinetic model for how the body processes.
Averaged out across the patients, they calculated, for example, that half
of the drug present absorbed was eliminated within 43 minutes. To find
out whether any patient characteristics affected the pharmacokinetics of
intra-rectal artesunate, the researchers used their model to estimate the
clearance of DHA from the body and the ability of DHA to spread
through the body (so-called apparent volume of distribution) for the
study patients. This analysis showed that only gender and weight
affected DHA pharmacokinetics. Finally, the researchers showed that
how well the parasite was cleared from the patients was not related to
these pharmacokinetic parameters, although the need for earlier rescue
treatment was associated with a larger volume of distribution for DHA.
Importantly, the parasitological response was not affected by the
estimated cumulative amount of DHA absorbed into the blood during
the first six hours after treatment.
What Do These Findings Mean? The data presented in this study
indicate that individual patients processed artesunate very differently in
terms of how they absorbed the drug and how it spread around the
body. Even so, the maximal effects of artesunate on the malaria parasite
were achieved rapidly in nearly all the patients. This and other
pharmacokinetic findings must be interpreted with caution, warn the
researchers, because their model included many assumptions to allow,
for example, for the variability of DHA concentrations both within
individual patients and between patients. Nevertheless, the findings
provide important clues about which patient characteristics might cause
early treatment failure, and indicate that artesunate is sufficiently well
absorbed via the rectal route in most patients to make artesunate
suppositories a promising first-line treatment for moderately severe
malaria.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030444.
 World Health Organization links to general information on malaria plus
specific information on rectal artesunate
 MedlinePlus encyclopedia entry on malaria
 US Centers for Disease Control and Prevention information on malaria
for patients and professionals
 Wikipedia pages on malaria and artemisinin (note that Wikipedia is a
free online encyclopedia that anyone can edit)
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